What Madorra does

Madorra is a Portland, Oregon-based women's health medical device company developing the Madorra Therapy System, a non-invasive, non-hormonal, home-use handheld device that applies therapeutic ultrasound waves to treat moderate to severe vulvovaginal atrophy (VVA). The company targets two primary customer segments: post-menopausal individuals experiencing vaginal dryness and atrophy, and breast cancer survivors who are often contraindicated for the hormonal therapies that dominate the existing standard of care. By offering a hardware-based alternative to topical hormones and moisturizers, Madorra is positioning itself as the first clinically validated non-pharmaceutical intervention in this category.

The Madorra Therapy System represents a single-product platform built around proprietary therapeutic ultrasound parameters and a handheld form factor intended for in-home use. The company received FDA Breakthrough Device Designation in September 2021 and enrolled the first patient in its pivotal WAVES Study in March 2026, indicating an active regulatory pathway rather than a commercial sales motion at present. Revenue mechanics will eventually depend on hardware sales through either direct-to-consumer or prescription channels, but the company is pre-revenue today and has not publicly disclosed pricing.

Madorra is venture-backed (most notably a $4.0M OneVentures-led round in September 2018) with additional support from the National Science Foundation, Portfolia, Stanford-affiliated StartX, Golden Seeds, HealthTech Capital, and a network of regional angel groups. The company operates with a 1–10 person team led by co-founder and CEO Holly Rockweiler, with a board that includes medtech operating experience and a clinical advisory bench of MDs spanning OB/GYN, oncology, and sexual medicine. Its stated objective is to change the treatment paradigm for vaginal dryness by giving patients a non-hormonal, non-invasive option that has historically only been served by pharmaceuticals.

Name

Madorra

Legal name

Madorra

Website

https://madorra.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Madorra is a Portland-based medical device company developing the Madorra Therapy System, a non-hormonal, non-invasive home-use handheld device that uses therapeutic ultrasound to treat vulvovaginal atrophy in post-menopausal individuals and breast cancer survivors.

Ownership category

akta.pro rank

Product category

Women's Health Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Nasal Drug Delivery Devices (Sprays/Powder Devices) (HLAHAIAK)

akta.pro secondary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Women's health devices
• Menopausal therapy
• Therapeutic ultrasound
• Non-hormonal treatment
• Femtech medical devices

Headquarters

HQ city

Portland

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Sales: Pre-revenue company currently in pivotal clinical trial stage. Revenue model will likely involve sales of the Madorra Therapy System, a home-use handheld medical device. The device targets post-menopausal individuals and breast cancer survivors with vulvovaginal atrophy.

Go-to-market motion1 record

Marketing channels2 records

Core offering

Madorra is developing a single medical device, the Madorra Therapy System, which is a non-invasive, non-hormonal, home-use handheld device that applies therapeutic ultrasound waves for the treatment of moderate to severe vulvovaginal atrophy (VVA) in post-menopausal individuals and breast cancer survivors. The product is currently in pivotal clinical trial (WAVES Study) following FDA Breakthrough Device Designation and is not yet commercially available.

Product overview

Madorra offers a single unified product: the Madorra Therapy System, a non-invasive, non-hormonal, home-use handheld device that applies therapeutic ultrasound waves for treating moderate to severe vulvovaginal atrophy. The company is currently conducting its pivotal clinical trial (the WAVES Study) as part of its regulatory pathway following FDA Breakthrough Device Designation status.

Differentiator

Problem solved

Functional benefit

Brands

• Madorra Therapy System: Non-invasive, non-hormonal, home-use handheld device applying therapeutic ultrasound waves for treating moderate to severe vulvovaginal atrophy (VVA).

Products and services

• Madorra Therapy System A non-invasive, non-hormonal, home-use handheld device that applies therapeutic ultrasound waves for the treatment of moderate to severe vulvovaginal atrophy (VVA). Targeted at post-menopausal individuals and breast cancer survivors who seek non-hormonal alternatives to existing pharmaceutical treatments.

Quantifiable outcome

• 80% participant adherence after 12 weeks of use
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Viveve Medical: Direct competitor developing energy-based (radiofrequency) medical devices for women's intimate health conditions including vaginal laxity and sexual function. Closest analog to Madorra in modality (energy-based device), indication area (vaginal tissue), and target customer (peri/post-menopausal women).
• InMode: Medical device company offering energy-based women's intimate health platforms (e.g., Morpheus8V, EmpowerRF) that treat vulvovaginal conditions. Directly competes with Madorra in the non-hormonal, device-based VVA treatment category using similar physician-office and home-use channels.

Broad incumbents

• Cynosure: Established aesthetics and women's health device maker (now part of Hologic) offering laser and RF-based platforms for vaginal rejuvenation and other indications. Comparable in modality (energy-based feminine health) but serves a broader aesthetic and dermatology portfolio beyond VVA.
• Hologic: Large women's health medtech incumbent spanning diagnostics, surgical devices, and (post-Cynosure acquisition) energy-based feminine health. Comparable in serving OB/GYNs and women's health channels, but with a far broader portfolio that makes it an acquirer or channel partner rather than a direct niche competitor.
• CooperSurgical: Major women's health medical device and consumables company (part of CooperCompanies) supplying OB/GYNs and reproductive medicine providers. Comparable in target customer (women's health clinicians) and channel, but covers fertility, surgical, and diagnostic categories rather than energy-based VVA therapy.

Emerging players

• Renovia: Women's health startup that developed the Leva pelvic floor device for urinary incontinence. Comparable in being a venture-backed, indication-focused women's health device company targeting post-partum and menopausal consumers with non-drug therapy, though focused on a different condition.
• Elitone: Developer of the Elitone non-invasive device for stress urinary incontinence in women. Comparable as a small, venture-backed women's health device company selling a home-use, non-pharmacological therapy to a similar demographic of older women, though addressing incontinence rather than VVA.
• Joylux: Femtech company offering energy-based home-use devices and products for vaginal rejuvenation and pelvic floor health. Comparable as a women's intimate health device startup targeting the same post-menopausal consumer with non-hormonal, device-based therapy, though smaller and earlier stage than Madorra.

Others

• Bayer (Women's Health): Pharmaceutical incumbent with established hormone-replacement products (e.g., Estring, Climara) for menopausal symptoms including VVA. Comparable as a major competitor addressing the same patient population via the incumbent hormonal approach that Madorra is positioning against; included as a competitive frame of reference rather than a direct device peer.
• Evernow: Digital health company providing telehealth and prescription-based menopause care including non-hormonal and hormonal VVA treatments. Comparable in serving post-menopausal women seeking alternatives to traditional hormone therapy, though delivered via services and prescriptions rather than a medical device.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MadorraMedical
• Facebookfacebook.com/MadorraMedical
• LinkedInlinkedin.com/company/madorra-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Madorra